Selected research
Industry Research
Active Hemostatic Agents Industry Research Report 2026
Market perspective
The global Active Hemostatic Agents market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Active Hemostatic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Active Hemostatic Agents is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Active Hemostatic Agents is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Active Hemostatic Agents include Stryker, Johnson & Johnson Services, Pfizer Inc., Baxter International Inc., Z-Medica LLC, Warrior Tactical, LLC, Medtronic Plc., Integra Life Sciences Corporation, etc. and GELITA GA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Active Hemostatic Agents market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Active Hemostatic Agents Market by Company
Stryker
Johnson & Johnson Services
Pfizer Inc.
Baxter International Inc.
Z-Medica LLC
Warrior Tactical, LLC
Medtronic Plc.
Integra Life Sciences Corporation, etc.
GELITA GA
Ethicon Inc.
CryoLife Inc.
C.R.Bard
Biom’up
BD
B. Braun Melsungen AG
Advanced Medical Solutions Group plc
Active Hemostatic Agents
Active Hemostatic Agents Segment by Type
Combination Products
Surgical Sealants
Thrombin based hemostats
Active Hemostatic Agents Segment by Application
Specialty Clinics
Hospitals
Ambulatory Surgical Centers
Active Hemostatic Agents Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Active Hemostatic Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Active Hemostatic Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Active Hemostatic Agents.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Active Hemostatic Agents manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Active Hemostatic Agents by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Active Hemostatic Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Combination Products
- Surgical Sealants
- Thrombin based hemostats
Applications
- Specialty Clinics
- Hospitals
- Ambulatory Surgical Centers
Companies covered
- Stryker
- Johnson & Johnson Services
- Pfizer Inc.
- Baxter International Inc.
- Z-Medica LLC
- Warrior Tactical, LLC
- Medtronic Plc.
- Integra Life Sciences Corporation, etc.
- GELITA GA
- Ethicon Inc.
- CryoLife Inc.
- C.R.Bard
- Biom’up
- BD
- B. Braun Melsungen AG
- Advanced Medical Solutions Group plc
- Active Hemostatic Agents
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Active Hemostatic Agents Market Size (2021-2032)
- 2.2.2 Global Active Hemostatic Agents Sales (2021-2032)
- 2.2.3 Global Active Hemostatic Agents Market Average Price (2021-2032)
- 2.3 Active Hemostatic Agents by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Combination Products
- 2.3.3 Surgical Sealants
- 2.3.4 Thrombin based hemostats
- 2.4 Active Hemostatic Agents by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Specialty Clinics
- 2.4.3 Hospitals
- 2.4.4 Ambulatory Surgical Centers
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Active Hemostatic Agents Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Active Hemostatic Agents Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Active Hemostatic Agents Revenue of Manufacturers (2021-2026)
- 3.4 Global Active Hemostatic Agents Average Price by Manufacturers (2021-2026)
- 3.5 Global Active Hemostatic Agents Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Active Hemostatic Agents, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Active Hemostatic Agents, Product Type & Application
- 3.8 Global Manufacturers of Active Hemostatic Agents, Established Date
- 3.9 Global Active Hemostatic Agents Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Stryker
- 4.1.1 Stryker Company Information
- 4.1.2 Stryker Business Overview
- 4.1.3 Stryker Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Stryker Active Hemostatic Agents Product Portfolio
- 4.1.5 Stryker Recent Developments
- 4.2 Johnson & Johnson Services
- 4.2.1 Johnson & Johnson Services Company Information
- 4.2.2 Johnson & Johnson Services Business Overview
- 4.2.3 Johnson & Johnson Services Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Services Active Hemostatic Agents Product Portfolio
- 4.2.5 Johnson & Johnson Services Recent Developments
- 4.3 Pfizer Inc.
- 4.3.1 Pfizer Inc. Company Information
- 4.3.2 Pfizer Inc. Business Overview
- 4.3.3 Pfizer Inc. Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Inc. Active Hemostatic Agents Product Portfolio
- 4.3.5 Pfizer Inc. Recent Developments
- 4.4 Baxter International Inc.
- 4.4.1 Baxter International Inc. Company Information
- 4.4.2 Baxter International Inc. Business Overview
- 4.4.3 Baxter International Inc. Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Baxter International Inc. Active Hemostatic Agents Product Portfolio
- 4.4.5 Baxter International Inc. Recent Developments
- 4.5 Z-Medica LLC
- 4.5.1 Z-Medica LLC Company Information
- 4.5.2 Z-Medica LLC Business Overview
- 4.5.3 Z-Medica LLC Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Z-Medica LLC Active Hemostatic Agents Product Portfolio
- 4.5.5 Z-Medica LLC Recent Developments
- 4.6 Warrior Tactical, LLC
- 4.6.1 Warrior Tactical, LLC Company Information
- 4.6.2 Warrior Tactical, LLC Business Overview
- 4.6.3 Warrior Tactical, LLC Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Warrior Tactical, LLC Active Hemostatic Agents Product Portfolio
- 4.6.5 Warrior Tactical, LLC Recent Developments
- 4.7 Medtronic Plc.
- 4.7.1 Medtronic Plc. Company Information
- 4.7.2 Medtronic Plc. Business Overview
- 4.7.3 Medtronic Plc. Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Medtronic Plc. Active Hemostatic Agents Product Portfolio
- 4.7.5 Medtronic Plc. Recent Developments
- 4.8 Integra Life Sciences Corporation, etc.
- 4.8.1 Integra Life Sciences Corporation, etc. Company Information
- 4.8.2 Integra Life Sciences Corporation, etc. Business Overview
- 4.8.3 Integra Life Sciences Corporation, etc. Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Integra Life Sciences Corporation, etc. Active Hemostatic Agents Product Portfolio
- 4.8.5 Integra Life Sciences Corporation, etc. Recent Developments
- 4.9 GELITA GA
- 4.9.1 GELITA GA Company Information
- 4.9.2 GELITA GA Business Overview
- 4.9.3 GELITA GA Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 GELITA GA Active Hemostatic Agents Product Portfolio
- 4.9.5 GELITA GA Recent Developments
- 4.10 Ethicon Inc.
- 4.10.1 Ethicon Inc. Company Information
- 4.10.2 Ethicon Inc. Business Overview
- 4.10.3 Ethicon Inc. Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Ethicon Inc. Active Hemostatic Agents Product Portfolio
- 4.10.5 Ethicon Inc. Recent Developments
- 4.11 CryoLife Inc.
- 4.11.1 CryoLife Inc. Company Information
- 4.11.2 CryoLife Inc. Business Overview
- 4.11.3 CryoLife Inc. Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 CryoLife Inc. Active Hemostatic Agents Product Portfolio
- 4.11.5 CryoLife Inc. Recent Developments
- 4.12 C.R.Bard
- 4.12.1 C.R.Bard Company Information
- 4.12.2 C.R.Bard Business Overview
- 4.12.3 C.R.Bard Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 C.R.Bard Active Hemostatic Agents Product Portfolio
- 4.12.5 C.R.Bard Recent Developments
- 4.13 Biom’up
- 4.13.1 Biom’up Company Information
- 4.13.2 Biom’up Business Overview
- 4.13.3 Biom’up Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Biom’up Active Hemostatic Agents Product Portfolio
- 4.13.5 Biom’up Recent Developments
- 4.14 BD
- 4.14.1 BD Company Information
- 4.14.2 BD Business Overview
- 4.14.3 BD Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 BD Active Hemostatic Agents Product Portfolio
- 4.14.5 BD Recent Developments
- 4.15 B. Braun Melsungen AG
- 4.15.1 B. Braun Melsungen AG Company Information
- 4.15.2 B. Braun Melsungen AG Business Overview
- 4.15.3 B. Braun Melsungen AG Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 B. Braun Melsungen AG Active Hemostatic Agents Product Portfolio
- 4.15.5 B. Braun Melsungen AG Recent Developments
- 4.16 Advanced Medical Solutions Group plc
- 4.16.1 Advanced Medical Solutions Group plc Company Information
- 4.16.2 Advanced Medical Solutions Group plc Business Overview
- 4.16.3 Advanced Medical Solutions Group plc Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Advanced Medical Solutions Group plc Active Hemostatic Agents Product Portfolio
- 4.16.5 Advanced Medical Solutions Group plc Recent Developments
- 4.17 Active Hemostatic Agents
- 4.17.1 Active Hemostatic Agents Company Information
- 4.17.2 Active Hemostatic Agents Business Overview
- 4.17.3 Active Hemostatic Agents Active Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Active Hemostatic Agents Active Hemostatic Agents Product Portfolio
- 4.17.5 Active Hemostatic Agents Recent Developments
5 Global Active Hemostatic Agents Market Scenario by Region
- 5.1 Global Active Hemostatic Agents Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Active Hemostatic Agents Sales by Region: 2021-2032
- 5.2.1 Global Active Hemostatic Agents Sales by Region: 2021-2026
- 5.2.2 Global Active Hemostatic Agents Sales by Region: 2027-2032
- 5.3 Global Active Hemostatic Agents Revenue by Region: 2021-2032
- 5.3.1 Global Active Hemostatic Agents Revenue by Region: 2021-2026
- 5.3.2 Global Active Hemostatic Agents Revenue by Region: 2027-2032
- 5.4 North America Active Hemostatic Agents Market Facts & Figures by Country
- 5.4.1 North America Active Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Active Hemostatic Agents Sales by Country (2021-2032)
- 5.4.3 North America Active Hemostatic Agents Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Active Hemostatic Agents Market Facts & Figures by Country
- 5.5.1 Europe Active Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Active Hemostatic Agents Sales by Country (2021-2032)
- 5.5.3 Europe Active Hemostatic Agents Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Active Hemostatic Agents Market Facts & Figures by Country
- 5.6.1 Asia Pacific Active Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Active Hemostatic Agents Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Active Hemostatic Agents Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Active Hemostatic Agents Market Facts & Figures by Country
- 5.7.1 South America Active Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Active Hemostatic Agents Sales by Country (2021-2032)
- 5.7.3 South America Active Hemostatic Agents Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Active Hemostatic Agents Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Active Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Active Hemostatic Agents Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Active Hemostatic Agents Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Active Hemostatic Agents Sales by Type (2021-2032)
- 6.1.1 Global Active Hemostatic Agents Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Active Hemostatic Agents Sales Market Share by Type (2021-2032)
- 6.2 Global Active Hemostatic Agents Revenue by Type (2021-2032)
- 6.2.1 Global Active Hemostatic Agents Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Active Hemostatic Agents Revenue Market Share by Type (2021-2032)
- 6.3 Global Active Hemostatic Agents Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Active Hemostatic Agents Sales by Application (2021-2032)
- 7.1.1 Global Active Hemostatic Agents Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Active Hemostatic Agents Sales Market Share by Application (2021-2032)
- 7.2 Global Active Hemostatic Agents Revenue by Application (2021-2032)
- 7.2.1 Global Active Hemostatic Agents Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Active Hemostatic Agents Revenue Market Share by Application (2021-2032)
- 7.3 Global Active Hemostatic Agents Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Active Hemostatic Agents Value Chain Analysis
- 8.1.1 Active Hemostatic Agents Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Active Hemostatic Agents Production Mode & Process
- 8.2 Active Hemostatic Agents Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Active Hemostatic Agents Distributors
- 8.2.3 Active Hemostatic Agents Customers
9 Global Active Hemostatic Agents Analyzing Market Dynamics
- 9.1 Active Hemostatic Agents Industry Trends
- 9.2 Active Hemostatic Agents Industry Drivers
- 9.3 Active Hemostatic Agents Industry Opportunities and Challenges
- 9.4 Active Hemostatic Agents Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst